Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.
1946
53K+
LTM Revenue $23.2B
LTM EBITDA $6.4B
$144B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Stryker has a last 12-month revenue of $23.2B and a last 12-month EBITDA of $6.4B.
In the most recent fiscal year, Stryker achieved revenue of $22.6B and an EBITDA of $5.7B.
Stryker expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Stryker valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $20.5B | $22.6B | XXX | XXX | XXX |
Gross Profit | $11.6B | $13.1B | XXX | XXX | XXX |
Gross Margin | 56% | 58% | XXX | XXX | XXX |
EBITDA | $4.9B | $5.7B | XXX | XXX | XXX |
EBITDA Margin | 24% | 25% | XXX | XXX | XXX |
Net Profit | $2.4B | $3.2B | XXX | XXX | XXX |
Net Margin | 12% | 14% | XXX | XXX | XXX |
Net Debt | $11.2B | $10.0B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Stryker's stock price is $353.
Stryker has current market cap of $135B, and EV of $144B.
See Stryker trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$144B | $135B | XXX | XXX | XXX | XXX | $12.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Stryker has market cap of $135B and EV of $144B.
Stryker's trades at 6.2x LTM EV/Revenue multiple, and 22.4x LTM EBITDA.
Analysts estimate Stryker's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Stryker and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $144B | XXX | XXX | XXX |
EV/Revenue | 6.4x | XXX | XXX | XXX |
EV/EBITDA | 25.2x | XXX | XXX | XXX |
P/E | 45.1x | XXX | XXX | XXX |
P/E/Growth | 1.2x | XXX | XXX | XXX |
EV/FCF | 41.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpStryker's NTM/LTM revenue growth is 8%
Stryker's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Stryker's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Stryker's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Stryker and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 10% | XXX | XXX | XXX | XXX |
EBITDA Margin | 25% | XXX | XXX | XXX | XXX |
EBITDA Growth | 16% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 34% | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
Opex to Revenue | 43% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Philips | XXX | XXX | XXX | XXX | XXX | XXX |
Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Stryker acquired XXX companies to date.
Last acquisition by Stryker was XXXXXXXX, XXXXX XXXXX XXXXXX . Stryker acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Stryker founded? | Stryker was founded in 1946. |
Where is Stryker headquartered? | Stryker is headquartered in United States of America. |
How many employees does Stryker have? | As of today, Stryker has 53K+ employees. |
Who is the CEO of Stryker? | Stryker's CEO is Mr. Kevin A. Lobo. |
Is Stryker publicy listed? | Yes, Stryker is a public company listed on NYS. |
What is the stock symbol of Stryker? | Stryker trades under SYK ticker. |
When did Stryker go public? | Stryker went public in 1988. |
Who are competitors of Stryker? | Similar companies to Stryker include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
What is the current market cap of Stryker? | Stryker's current market cap is $135B |
What is the current revenue of Stryker? | Stryker's last 12-month revenue is $23.2B. |
What is the current EBITDA of Stryker? | Stryker's last 12-month EBITDA is $6.4B. |
What is the current EV/Revenue multiple of Stryker? | Current revenue multiple of Stryker is 6.2x. |
What is the current EV/EBITDA multiple of Stryker? | Current EBITDA multiple of Stryker is 22.4x. |
What is the current revenue growth of Stryker? | Stryker revenue growth between 2023 and 2024 was 10%. |
Is Stryker profitable? | Yes, Stryker is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.